FIB-4 ≥1.3 is correlated with increased DKD risk in T2D, but SGLT2i therapy that lowers FIB-4 attenuates this . d [Internet]. 2025 Dec. 15 [cited 2026 Apr. 14];3(4):120-7. Available from: https://thediabzen.com/index.php/d/article/view/34